About Us

Contact Us

Race
Home About Us Product News Order Career Contact

                                                                                                            

           APIs&Intermediates Chemicals of Shanghai APIs Chemical Co., Ltd 

       

Product Indentification
 

 

Name:   BIBF-1120
Synonyms:   BIBF-1120;(Z)-methyl 3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate
CAS Registry Number:   928326-83-4
Molecular Formula:   C31H33N5O4
Molecular Weight:    539.62
Molecular Structure:    

                                           

                     3D Structure:                     

                           

                    In stock!

 

                   Appearance: light yellow powder

 

                   Purity:99%min                                           

 

                   MP:214 °C

 

                   Storage: 4 deg C

 

                  Inquiry (H1NMR,HPLC,LC-MS)

 

 

Related pages:


     Search BIBF-1120 in google
     Search CAS 928326-83-4  in google
     Search C31H33N5O4  in google

 

Related News:

 

BIBF 1120 (Vargatef) is a novel triple angiokinase inhibitor that inhibits three growth factor receptors simultaneously: vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR). All three growth factors are crucially involved in the formation of blood vessels (angiogenesis) and inhibition of them may play a critical role in the prevention of tumour growth and spread.

BIBF 1120 (Vargatef) is currently being investigated in a number of indications including advanced non-small cell lung cancer (NSCLC), prostate cancer, ovarian cancer and colorectal cancer.

 

 

Mechanism of action (From BI fact sheet ):

 

     Angiogenesis is an important natural process occurring in the body, both in health and in disease. In a healthy body, angiogenesis occurs in wound healing and to restore blood flow to damaged tissues. However, excessive angiogenesis occurs in diseases such as solid cancer, in which the new blood vessels feed diseased tissues with oxygen and nutrients, encouraging tumour growth and spread (metastases).

 

     The process of tumour angiogenesis starts with cancerous tumour cells releasing molecules that send ‘signals’ to surrounding normal healthy tissue. Angiogenesis inhibitors, such as BIBF 1120 (Vargatef™), interfere with steps in the angiogenesis signalling cascade therefore preventing growth and spread of the tumour. BIBF 1120 (Vargatef™) targets three receptor classes involved in angiogenesis:

 

• VEGFR – Vascular Endothelial Growth Factor Receptors. For instance VEGFR 2 regulates the proliferation and migration
of cells that create blood vessels
• PDGFR – Platelet Derived Growth Factor Receptors control the migration and adherence of cells the provide support and stability to vessel walls
• FGFR – Fibroblast Growth Factor Receptors also control the migration and adherence of cells that provide support and stability to vessel walls
    BIBF 1120 (Vargatef™) is an investigational compound. Its safety and efficacy have not yet been fully established.


BIBF 1120 (Vargatef™)’s inhibition of VEGFR and FGFR is thought to have an impact on the formation of new tumour blood vessels and its inhibition of FGFR and PDGFR may have an effect on the maintenance of the vascular integrity.
 

                   

          

 

 

      We have developed the synthesis process of this product in 2011 and have this compound in stock now,  looking forward to cooperating with you!!

 

                         All of our APIs products are for research use only. Not for human use. We do not sell to patients.

 

 

Home About Us Product News Order Career Contact
 Copyright @ 2010-2011 APIs All rights reserved
 

 

 

No_Right_Click

 

No_Right_Click